Gene Expression Changes of Drug-resistant Saos-2 Cells Induced by Anticancer Drug.
- Author:
Min Jae BAE
1
;
In Hwan SONG
;
Seong Yong KIM
Author Information
1. Department of Biochemistry and Molecular Biology, College of Medicine, Yeungnam University, Daegu, Korea. seongyong@med.yu.ac.kr
- Publication Type:Original Article
- Keywords:
Anticancer durg-resistant;
Adriamycin;
cDNA microarray;
Cisplatin;
Gene expression;
Vincristine;
Saos-2
- MeSH:
Cell Line;
Cisplatin;
Doxorubicin;
Drug Resistance;
Gene Expression*;
Humans;
Oligonucleotide Array Sequence Analysis;
Recurrence;
RNA;
Survival Rate;
Vincristine
- From:Korean Journal of Anatomy
2007;40(4):297-310
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
During the treatment of cancers, especially with anticancer drugs, the recurrence of cancer is the most important factor for survival rate. The most common cause of the recurrence is the resistance of cells to anticancer drugs. To explore and analyze the changes of gene expression during the induction of resistance by anticancer drugs in human osteogenic cancer cell line Saos-2. The drug resistance was induced with adriamycin, cisplatin or vincristine at 10(-7) M concentration of each and cDNA microarray was performed. Total RNA was purified from Saos-2, adriamycin-resistant (Saos-2AdR), cisplatin-resistant (Saos-2CpR) and vincristine-resistant (Saos-2VcR) and expressed genes were investigated with a Affymetrix Human HG-U133Plus2.0 GeneChip(TM). The genes of anticancer drug resistant cells that showed more than 2.5 fold expression change than Saos-2 were selected for differential expression. Four hundred seventeen genes were selected for Saos-2 vs Saos-2AdR. Two thousand five hundred thirty six genes were selected for Saos-2 vs Saos-2CpR. Two hundred twenty five genes were selected for Saos-2 vs Saos-2VcR. Eighty seven genes were selected for common differential expression. The results showed that many genes were changed in expression during the acquiring of resistance to anticancer drugs but most of genes were not in common among the three anticancer durg-resistant Saos-2. This means the different anticancer drug takes the different mechanism for acquiring resistance to anticancer drug even we use same cells.
